Download PDF
Semin Thromb Hemost 2014; 40(07): 790-802
DOI: 10.1055/s-0034-1384636
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Emerging Therapies for Hemophilia: A New Era of Care and the Role of the Interdisciplinary Team

Michelle Witkop
1   Northern Regional Bleeding Disorders Center, Traverse City, Michigan
,
Susan Cutter
2   Penn Comprehensive Hemophilia and Thrombosis Program, University of Pennsylvania, Philadelphia, Pennsylvania
,
Joann Deutsche
3   Oregon Hemophilia Center, Oregon Health and Science Center, Portland, Oregon
,
Maria Santaella
4   Miami Hemophilia Treatment Center, University of Miami Miller School of Medicine, Miami, Florida
,
Robin Chapman
5   Children's Healthcare of Atlanta, Atlanta, Georgia
,
Jennifer Lafranco
6   Clinical Programs, Mary M. Gooley Hemophilia Center, Rochester General, Rochester, New York
,
Angela Lambing
7   Henry Ford Hospital, Hemophilia Treatment Center, Detroit, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
21 August 2014 (online)

    Permissions and Reprints

Abstract

The introduction of new hemophilia management therapies, targeting extended half-lives through bioengineering, ushers in an era of potential promise and increasing complexity, more so for those with hemophilia B than hemophilia A. Questions arise for patients, caregivers, and hemophilia treatment center (HTC) staff about how to assess and incorporate novel therapies and how to determine whether new therapies offer a distinct advantage over established treatment routines. Nurses and other interdisciplinary HTC staff are well positioned to assess, educate, and support patients and families in navigating this rapidly changing landscape. To support these challenging efforts, this review offers a perspective on issues affecting therapeutic transitions and provides tools to foster ongoing adherence.

Keywords

hemophilia - therapy transition - adherence - cultural - psychosocial
 

  • References

  • 1 Powell JS, Pasi KJ, Ragni MV , et al; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369 (24) 2313-2323
    CrossrefPubMedGoogle Scholar
  • 2 Shapiro AD, Ragni MV, Valentino LA , et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119 (3) 666-672
    CrossrefPubMedGoogle Scholar
  • 3 biogen idec. Alprolix™ [Coagulation factor IX (recombinant), Fc fusion protein]. Highlights of prescribing information. Available at: http://www.alprolix.com/pdfs/PrescribingInformation.pdf Accessed May 9, 2014.
    PubMedGoogle Scholar
  • 4 Powell JS, Josephson NC, Quon D , et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119 (13) 3031-3037
    CrossrefPubMedGoogle Scholar
  • 5 Mahlangu J, Powell JS, Ragni MV , et al; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123 (3) 317-325
    CrossrefPubMedGoogle Scholar
  • 6 Santagostino E, Negrier C, Klamroth R , et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120 (12) 2405-2411
    CrossrefPubMedGoogle Scholar
  • 7 Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013; 131 (Suppl. 02) S2-S6
    CrossrefPubMedGoogle Scholar
  • 8 Turecek PL, Bossard MJ, Graninger M , et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie 2012; 32 (Suppl. 01) S29-S38
    PubMedGoogle Scholar
  • 9 Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12 (4) 488-496
    CrossrefPubMedGoogle Scholar
  • 10 Gu JM, Ramsey P, Evans V , et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A. Haemophilia 2014; 20 (4) 593-600
    CrossrefPubMedGoogle Scholar
  • 11 Tiede A, Brand B, Fischer R , et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11 (4) 670-678
    CrossrefPubMedGoogle Scholar
  • 12 Novo Nordisk. March 19, 2014. Positive results from first phase 3 trial with N8-GP, a long-acting factor VIII for treatment of haemophilia A. Available at: http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=31C49463-5E29-4262-9E4D-F8C47E96A57B Accessed May 16, 2014.
    PubMedGoogle Scholar
  • 13 Østergaard H, Bjelke JR, Hansen L , et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 2011; 118 (8) 2333-2341
    CrossrefPubMedGoogle Scholar
  • 14 Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118 (10) 2695-2701
    CrossrefPubMedGoogle Scholar
  • 15 Liesner R, Jansen M, Klukowska A, Vdovin V, Szczepanski T, Knaub S. Efficacy, immunogenicity, pharmacokinetics, and safety of human-cl rhFVIII—a GCP study in children with severe haemophilia A. Blood 2013; 122 (21) 3594
    PubMedGoogle Scholar
  • 16 Valentino LA, Negrier C, Kohla G , et al. The first recombinant FVIII produced in human cells—an update on its clinical development programme. Haemophilia 2014; 20 (Suppl. 01) 1-9
    PubMedGoogle Scholar
  • 17 Pruthi RK. Laboratory monitoring of new hemostatic agents. Presented at: Thrombosis & Hemostasis Summit of North American 2014 , Chicago, IL. Available at: http://www.thsna.org/Presentation_Upload/presentation_uploads/69_26_Pruthi%20Laboratory%20Monitoring%20of%20newer%20hemostatic%20agents%20Final.pdf Accessed May 2, 2014
    PubMedGoogle Scholar
  • 18 Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38 (1) 79-94
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Manco-Johnson MJ, Abshire TC, Shapiro AD , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (6) 535-544
    CrossrefPubMedGoogle Scholar
  • 20 National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Document #179. MASAC Recommendation Concerning Prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at: http://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/All-MASAC-Recommendations/Recommendation-Concerning-Prophylaxis. Accessed July 3, 2014
    PubMedGoogle Scholar
  • 21 Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87 (Suppl. 01) S33-S39
    CrossrefPubMedGoogle Scholar
  • 22 Powell J, Josephson NC, Quon D , et al. Pharmacokinetics and safety of recombinant factor VIII Fc fusion protein (rFVIIIFc) in a phase 1/2A trial in previously treated patients (PTPS) with severe hemophilia A. J Thromb Haemost 2011; 9 (Suppl. 02) 283 . Abstract O-TU-073
    CrossrefPubMedGoogle Scholar
  • 23 Lillicrap D. The future of hemostasis management. Pediatr Blood Cancer 2013; 60 (Suppl. 01) S44-S47
    CrossrefPubMedGoogle Scholar
  • 24 Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology (Am Soc Hematol Educ Program) 2011; 2011: 397-404
    CrossrefPubMedGoogle Scholar
  • 25 Branchford BR, Monahan PE, Di Paola J. New developments in the treatment of pediatric hemophilia and bleeding disorders. Curr Opin Pediatr 2013; 25 (1) 23-30
    CrossrefPubMedGoogle Scholar
  • 26 Pipe SW. Hemophilia: new protein therapeutics. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 203-209
    CrossrefPubMedGoogle Scholar
  • 27 Young G. From boy to man: recommendations for the transition process in haemophilia. Haemophilia 2012; 18 (Suppl. 05) 27-32
    CrossrefPubMedGoogle Scholar
  • 28 van Staa AL, Jedeloo S, van Meeteren J, Latour JM. Crossing the transition chasm: experiences and recommendations for improving transitional care of young adults, parents and providers. Child Care Health Dev 2011; 37 (6) 821-832
    CrossrefPubMedGoogle Scholar
  • 29 Young G. Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population. Blood Coagul Fibrinolysis 2010; 21 (Suppl. 01) S7-S10
    CrossrefPubMedGoogle Scholar
  • 30 Ljung R, Auerswald G, Benson G , et al. Novel coagulation factor concentrates: issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia 2013; 19 (4) 481-486
    CrossrefPubMedGoogle Scholar
  • 31 Khair K, Gibson F, Meerabeau L. The benefits of prophylaxis: views of adolescents with severe haemophilia. Haemophilia 2012; 18 (3) e286-e289
    CrossrefPubMedGoogle Scholar
  • 32 du Treil S, Rice J, Leissinger CA. Maintenance of treatment logs by haemophilia patients. Haemophilia 2010; 16 (3) 545-547
    PubMedGoogle Scholar
  • 33 Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125 (6) 1004-1009
    CrossrefPubMedGoogle Scholar
  • 34 Vidovic N, Musso R, Klamroth R, Enriquez MM, Achilles K. Postmarketing surveillance study of KOGENATE Bayer with Bio-Set in patients with haemophilia A: evaluation of patients' satisfaction after switch to the new reconstitution system. Haemophilia 2010; 16 (1) 66-71
    CrossrefPubMedGoogle Scholar
  • 35 World Health Organization. Adherence to long-term therapies: evidence for action. Available at: http://www.who.int/chp/knowledge/publications/adherence_report/en/ Accessed March 12, 2013
    PubMedGoogle Scholar
  • 36 Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag 2005; 1 (3) 189-199
    PubMedGoogle Scholar
  • 37 De Moerloose P, Urbancik W, Van Den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14 (5) 931-938
    CrossrefPubMedGoogle Scholar
  • 38 Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy — global progress towards optimal care. Haemophilia 2006; 12 (1) 75-81
    PubMedGoogle Scholar
  • 39 Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K. Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia 2013; 19 (3) 355-361
    CrossrefPubMedGoogle Scholar
  • 40 Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs 2010; 42 (5, Suppl): S10-S18
    CrossrefPubMedGoogle Scholar
  • 41 Farmer A, Hardeman W, Hughes D , et al. An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes. BMC Fam Pract 2012; 13: 30
    CrossrefPubMedGoogle Scholar
  • 42 Bombardier CH, Cunniffe M, Wadhwani R, Gibbons LE, Blake KD, Kraft GH. The efficacy of telephone counseling for health promotion in people with multiple sclerosis: a randomized controlled trial. Arch Phys Med Rehabil 2008; 89 (10) 1849-1856
    CrossrefPubMedGoogle Scholar
  • 43 Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17 (5) e901-e905
    PubMedGoogle Scholar
  • 44 Coleman CI, Limone B, Sobieraj DM , et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18 (7) 527-539
    CrossrefPubMedGoogle Scholar
  • 45 Duncan NA, Kronenberger WG, Roberson CP, Shapiro AD. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia 2010; 16 (1) 47-53
    CrossrefPubMedGoogle Scholar
  • 46 Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia 2010; 16 (2) 247-255
    CrossrefPubMedGoogle Scholar
  • 47 Baker JR, Riske B, Voutsis M, Cutter S, Presley R. Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia. Am J Prev Med 2011; 41 (6) (Suppl. 04) S338-S345
    CrossrefPubMedGoogle Scholar
  • 48 Kyngäs H. Compliance of adolescents with chronic disease. J Clin Nurs 2000; 9 (4) 549-556
    CrossrefPubMedGoogle Scholar
  • 49 Thornburg CD, Carpenter S, Zappa S, Munn J, Leissinger C. Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States. Haemophilia 2012; 18 (4) 568-574
    CrossrefPubMedGoogle Scholar
  • 50 Simpson Jr RJ. Challenges for improving medication adherence. JAMA 2006; 296 (21) 2614-2616
    CrossrefPubMedGoogle Scholar
  • 51 Paper R. Becoming a partner in your healthcare. Haemophilia 2002; 8 (3) 447-449
    CrossrefPubMedGoogle Scholar
  • 52 Steinhart B. Patient autonomy: evolution of the doctor-patient relationship. Haemophilia 2002; 8 (3) 441-446
    CrossrefPubMedGoogle Scholar
  • 53 Charles C, Gafni A, Whelan T, O'Brien MA. Cultural influences on the physician-patient encounter: The case of shared treatment decision-making. Patient Educ Couns 2006; 63 (3) 262-267
    CrossrefPubMedGoogle Scholar
  • 54 Harris JL, Fleming VB, Harris CL. A focus on health beliefs: what culturally competent clinicians need to know. Perspectives on Communication Disorders and Sciences in Culturally and Linguistically Diverse Populations 2012; 19: 40-48
    CrossrefPubMedGoogle Scholar
  • 55 Aslam F, Aftab O, Janjua NZ. Medical decision making: the family-doctor-patient triad. PLoS Med 2005; 2 (6) e129
    CrossrefPubMedGoogle Scholar
  • 56 Katz JN, Lyons N, Wolff LS , et al. Medical decision-making among Hispanics and non-Hispanic Whites with chronic back and knee pain: a qualitative study. BMC Musculoskelet Disord 2011; 12: 78
    CrossrefPubMedGoogle Scholar
  • 57 McLaughlin LA, Braun KL. Asian and Pacific Islander cultural values: considerations for health care decision making. Health Soc Work 1998; 23 (2) 116-126
    CrossrefPubMedGoogle Scholar
  • 58 Kaiser Permanente National Diversity Council. A provider's handbook on culturally competent care: Latino population. Available at: http://kphci.org/downloads/KP.PHandbook.Latino.1st.1996.pdf Accessed March 12, 2014
    PubMedGoogle Scholar
  • 59 Becenti J, Wick KH. Tradition and treatment: the impact of cultural beliefs on medical decision making. JAAPA 2006; 19 (12) 16-18
    PubMedGoogle Scholar
  • 60 Maly RC, Umezawa Y, Ratliff CT, Leake B. Racial/ethnic group differences in treatment decision-making and treatment received among older breast carcinoma patients. Cancer 2006; 106 (4) 957-965
    CrossrefPubMedGoogle Scholar
  • 61 Scott CJ. Enhancing patient outcomes through an understanding of intercultural medicine: guidelines for the practitioner. Md Med J 1997; 46 (4) 175-180
    PubMedGoogle Scholar
  • 62 Juckett G. Caring for Latino patients. Am Fam Physician 2013; 87 (1) 48-54
    PubMedGoogle Scholar
  • 63 Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11 (Suppl. 01) 84-98
    CrossrefPubMedGoogle Scholar
  • 64 Skinner MW. WFH: closing the global gap—achieving optimal care. Haemophilia 2012; 18 (Suppl. 04) 1-12
    PubMedGoogle Scholar
  • 65 Chou R, Fanciullo GJ, Fine PG , et al; American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10 (2) 113-130
    CrossrefPubMedGoogle Scholar
  • 66 Volk ML, Lieber SR, Kim SY, Ubel PA, Schneider CE. Contracts with patients in clinical practice. Lancet 2012; 379 (9810) 7-9
    CrossrefPubMedGoogle Scholar
  • 67 Lieber SR, Kim SY, Volk ML. Power and control: contracts and the patient-physician relationship. Int J Clin Pract 2011; 65 (12) 1214-1217
    CrossrefPubMedGoogle Scholar
  • 68 Bosch-Capblanch X, Abba K, Prictor M, Garner P. Contracts between patients and healthcare practitioners for improving patients' adherence to treatment, prevention and health promotion activities. Cochrane Database Syst Rev 2007; (2) CD004808
    PubMedGoogle Scholar
  • 69 du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13 (5) 493-501
    CrossrefPubMedGoogle Scholar
  • 70 Ruffo S, Messori A, Grasela TH , et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed 1985; 19 (2-3) 167-177
    CrossrefPubMedGoogle Scholar
  • 71 Brookes L. Medscape Education. Methods to Improve Adherence: The FAME Trial. Available at: http://www.medscape.org/viewarticle/552105 Accessed March 12, 2014
    PubMedGoogle Scholar
  • 72 Halpern SD, Asch DA, Volpp KG. Commitment contracts as a way to health. BMJ 2012; 344: e522
    CrossrefPubMedGoogle Scholar
  • 73 Pipe SW. The physician's role in selecting a factor replacement therapy. Haemophilia 2006; 12 (Suppl. 01) 21-25 , discussion 26–28
    CrossrefPubMedGoogle Scholar
  • 74 Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data. J Neurosci Nurs 2010; 42 (5, Suppl): S5-S9
    CrossrefPubMedGoogle Scholar
  • 75 Scheiner G, Sobel RJ, Smith DE , et al. Insulin pump therapy: guidelines for successful outcomes. Diabetes Educ 2009; 35 (Suppl. 02) 29S-41 S, quiz 28S, 42S–43S
    CrossrefPubMedGoogle Scholar
  • 76 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (1) 2-10
    CrossrefPubMedGoogle Scholar
  • 77 den Uijl JE, Fischer K, Van DerBom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17 (1) 41-44
    CrossrefPubMedGoogle Scholar
  • 78 Mannucci PM. Treatment of haemophilia: building on strength in the third millennium. Haemophilia 2011; 17 (Suppl. 03) 1-24
    PubMedGoogle Scholar
  • 79 Richards M, Altisent C, Batorova A , et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia 2007; 13 (5) 473-479
    CrossrefPubMedGoogle Scholar
  • 80 Valentino LA, Ismael Y, Grygotis M. Novel drugs to treat hemophilia. Expert Opin Emerg Drugs 2010; 15 (4) 597-613
    CrossrefPubMedGoogle Scholar
  • 81 Gouw SC, van der Bom JG, Ljung R , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (3) 231-239
    CrossrefPubMedGoogle Scholar
  • 82 Franchini M, Coppola A, Rocino A , et al; Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39 (7) 752-766
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4693-4697
    CrossrefPubMedGoogle Scholar
  • 84 Chalmers EA, Brown SA, Keeling D , et al; Paediatric Working Party of UKHCDO. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13 (2) 149-155
    CrossrefPubMedGoogle Scholar
  • 85 Mei B, Pan C, Jiang H , et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116 (2) 270-279
    CrossrefPubMedGoogle Scholar
  • 86 National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Document #132. MASAC Standards and Criteria for the Care of Persons with Congenital Bleeding Disorders. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=220 Accessed March 31, 2014
    PubMedGoogle Scholar
  • 87 National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) Document #218. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=693 Accessed March 31, 2014
    PubMedGoogle Scholar